HLB (028300) Q3 2025 earnings summary

Executive summary

• Operates in healthcare, bio-pharmaceuticals, and composite materials, with a focus on diagnostic medical devices, anti-cancer drug development, and specialty shipbuilding.

• Expanded global presence through subsidiaries and strategic investments, including Elevar Therapeutics and Immunomic Therapeutics.

• Recent business restructuring includes the spin-off of the shipbuilding division and increased focus on healthcare and bio segments.

Financial highlights

• Consolidated revenue for the first three quarters of 2025 was KRW 55.5 billion, down from KRW 68.1 billion in the same period last year.

• Operating loss for the period was KRW 74.8 billion, compared to a loss of KRW 118.5 billion year-over-year.

• Net loss attributable to owners was KRW 195.0 billion, a significant increase from KRW 92.0 billion in the prior year.

• Cash and cash equivalents at period end were KRW 42.9 billion, down from KRW 93.0 billion at the previous year-end.

Outlook and guidance

• Plans to accelerate commercialization of anti-cancer drugs, especially Rivoceranib and Lirafugratinib, with ongoing regulatory submissions in the US and Europe.

• Continued expansion in global markets, with a focus on new product launches in healthcare and bio segments.

• Strategic investments in R&D and pipeline expansion expected to drive future growth.